There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: I, a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination
HODGKIN LYMPHOMA THERAPY - Cessione una tantum, irrevocabile ed in via esclusiva a Mundipharma EDO GmbH/PURDUE del proprio diritto di titolarità al brevetto, domanda nr. US 2018/0098969A1 la cui procedura di concessione è tuttora in itinere e dove la sottoscritta compare tra i co-inventori / Mehrling, Thomas; DE FILIPPI, Rosaria; Pinto, Antonello. - (2018).
HODGKIN LYMPHOMA THERAPY - Cessione una tantum, irrevocabile ed in via esclusiva a Mundipharma EDO GmbH/PURDUE del proprio diritto di titolarità al brevetto, domanda nr. US 2018/0098969A1 la cui procedura di concessione è tuttora in itinere e dove la sottoscritta compare tra i co-inventori.
DE FILIPPI ROSARIA
;
2018
Abstract
There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: I, a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combinationI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.